

Supplemental Table S1. Factors Associated with Age Disparities – PMEC10.					
Trial/Author Characteristics		Number of trials	Mean DMA (SE), years	Univariable p-value*	Multivariable regression p-value
All		723	-5.82 (0.23)	-	-
PMEC-10	Yes	67	-8.52 (0.84)	<0.001	<0.001
	No	656	-5.54 (0.24)	-	
Industry funding of trial	Yes	585	-5.87 (0.26)	0.25	-
	No	138	-5.58 (0.53)	-	-
Cooperative Group Trial	Yes	182	-5.97 (0.46)	0.92	-
	No	541	-5.77 (0.27)	-	-
Enrollment Start Year	1991-2000	30	-4.19 (0.97)	0.64	-
	2001-2005	133	-6.62 (0.52)	-	-
	2006-2010	315	-5.70 (0.37)	-	-
	2011-2015	191	-5.79 (0.45)	-	-
	2016-2020	54	-5.57 (0.75)	-	-
Disease Site [†]	Breast	142	-7.05 (0.46)	0.012	0.56
	Gastrointestinal	97	-7.97 (0.45)	<0.001	0.043
	Genitourinary	98	-0.45 (0.57)	<0.001	<0.001
	Head & Neck	30	-2.46 (1.06)	0.003	<0.001
	Skin	29	-5.74 (0.82)	0.97	-
	Thoracic	126	-9.05 (0.32)	<0.001	<0.001
	Hematologic	144	-6.62 (0.59)	0.57	-
	Other	57	-0.98 (0.86)	<0.001	<0.001
Treatment modality [§]	Systemic therapy	624	-5.97 (0.25)	0.028	0.72
	Radiotherapy	15	-2.92 (1.03)	0.029	0.28
	Surgery	5	-10.44 (4.48)	0.45	-
	Supportive Care	79	-4.92 (0.68)	0.11	-
Targeted Therapy	Yes	454	-6.18 (0.29)	0.019	0.32
	No	269	-5.19 (0.39)	-	-
Completed planned accrual [#]	Yes	417	-5.48 (0.31)	0.08	-
	No	154	-6.61 (0.52)	-	-
Trial success (PEP met) [^]	Yes	344	-5.63 (0.36)	0.65	-
	No	299	-5.90 (0.34)	-	-

Abbreviations: PMEC-10, prior malignancy exclusion criteria for prior cancers within 10 years/indefinitely.

*P-value reflects Mann-Whitney *U*-test, except for Disease Site and Treatment Modality (for which the Kruskal-Wallis test was used) and Enrollment Start Year (for which a linear regression was conducted).

‡Limited to trials with a defined single disease site. “Other” includes trials of other single disease sites. Trials with multiple disease sites were excluded.

§Primary intervention as part of the randomization. Systemic therapy includes cytotoxic chemotherapy, targeted systemic agents, and similar, with primary endpoint aimed at improved disease-related outcomes. Supportive care trials aimed to reduce disease- or treatment-related toxicity.

#152 trials did not have final accrual data, in some cases due to trial ongoing.

^100 trials either had multiple PEPs with mixed results or did not have any associated publication